Allogene Therapeutics is a clinical stage immuno-oncology company focused on the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. Several of the company's key product candidates, including UCART19, ALLO-501 and ALLO-501A, are engineered allogeneic CAR T cell therapies that target CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. The company is developing an anti-CD52 monoclonal antibody, ALLO-647, which is designed to be used prior to infusing its other product candidates as part of the lymphodepletion regimen.

Apyx Medical is an energy technology company with products in the cosmetic and surgical markets. The company's segments are: Advanced Energy, which cosists of Renuvion? that provides plastic surgeons, facial plastic surgeons and cosmetic physicians an ability to provide controlled heat to the tissue, and the J-Plasma? system that allows surgeons to operate with precision, virtually eliminating unintended tissue trauma, which this technology is indicated for the cutting, coagulation and ablation of soft tissue; and Original Equipment Manufacturing, which designs, develops and manufactures electrosurgical equipment by producing generators and related accessories for medical device manufacturers.

Beam Therapeutics operates as a biotechnology company. Through its subsidiaries, the company is a research stage biotechnology company committed to creating a new class of precision genetic medicines, based on the company's proprietary base editing technology, with a vision of providing life-long cures to patients suffering from serious diseases.

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing muscle activators and muscle inhibitors as treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company's clinical-stage drug candidates are: omecamtiv mecarbil, a cardiac myosin activator for the treatment of heart failure, AMG 594, a cardiac troponin activator, reldesemtiv, a skeletal muscle troponin activator for the treatments of spinal muscular atrophy and amyotrophic lateral sclerosis, and CK-3773274, a cardiac myosin inhibitor which is designed to reduce the hypercontractility that is associated with hypertrophic cardiomyopathy.

Denali Therapeutics is a biopharmaceutical company that discovers and develops therapeutics to defeat neurodegenerative diseases. The company's target indications include diseases, such as Alzheimer's disease and Parkinson's disease, as well as orphan indications, such as mucopolysaccharidosis type II, and amyotrophic lateral sclerosis. The company's Transport Vehicle technology enables several classes of biotherapeutics to cross the blood-brain barrier (BBB), including enzymes, antibodies, proteins and oligonucleotides. This technology is designed to engage BBB transport receptors, which are expressed in brain capillaries and facilitate transport of proteins into the brain.

Donnelley Financial Solutions is a risk and compliance solutions company. The company provides regulatory filing and deal solutions via its software-as-a-service, print and distribution solutions to public and private companies, mutual funds and other regulated investment firms. For corporate clients within its capital markets offerings, the company provides filing solutions that allow U.S. public companies to comply with applicable U.S. Securities and Exchange Commission regulations. The company operates in two business segments: U.S, which is comprised of capital markets, investment markets, and language solutions; and International, which includes operations in Asia, Europe, Canada, and Latin America.

Dynavax Technologies is a biopharmaceutical company focused on utilizing the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company's commercial product, HEPLISAV-B? (Hepatitis B Vaccine (Recombinant), Adjuvanted), is approved for prevention of infection caused by various known subtypes of hepatitis B virus in adults age 18 years and older. The company's development efforts are focused on stimulating the innate immune response to treat cancer in combination with other immunomodulatory agents. The company's pipeline of product candidates includes: SD-101, which is its cancer immunotherapy candidate; and DV281, which is an investigational TLR9 agonist.

Everi Holdings, through its subsidiaries, is a supplier of technology solutions for the casino gaming industry. The company has two segments: Games, which provides solutions directly to gaming establishments to provide their patrons gaming entertainment- related experiences including: leased gaming equipment, sales and maintenance-related services of gaming equipment, among others; and FinTech, which provides solutions to gaming establishments to provide their patrons cash access related services and products including: access to cash at gaming facilities via automated teller machine cash withdrawals, credit card cash access transactions and point of sale debit card cash access transactions.

EVO Payments is a payment technology and services provider, providing an array of payment solutions to merchants. The company provides card-based payment processing services to small and middle market merchants, multinational corporations, government agencies, and other business and nonprofit enterprises. These services enable merchants to accept credit and debit cards and other electronic payment methods as payment for their products and services by providing terminal devices, card authorization, data capture, funds settlement, risk management, fraud detection, and chargeback services. The company operates in two reportable segments: North America and Europe.

ExlService Holdings is a holding company. Through its subsidiaries, the company is an operations management and analytics company. The company's operations management services involve the transfer to the company's business operations of a client such as claims processing, clinical operations, or financial transaction processing, after which the company administers and manages those operations for its client on an ongoing basis, or in case of consulting, consulting services related to transformation services, including digital transformation services. The company's Analytics services focus on driving business outcomes for its customers by generating data-driven insights across various parts of its customers' business.

Global Blood Therapeutics is a biopharmaceutical company that engages in the discovery, development and delivery of treatments to underserved patient communities. The company received U.S. Food and Drug Administration accelerated approval for its medicine, Oxbryta? (voxelotor) tablets for the treatment of sickle cell disease (SCD) in adults and children 12 years of age and older. Oxbryta, an oral therapy taken once daily, is the treatment that directly inhibits sickle hemoglobin polymerization, the root cause of SCD. The company is developing its SCD pipeline with inclacumab, a p-selectin inhibitor in development to address pain crises associated with the disease.

Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in immunology, inflammation and oncology. The company has four clinical-stage product candidates: GB001 (Prostaglandin D2 receptor 2 Antagonist), which is for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions; GB002 (Platelet-derived growth factor Receptor Kinase Inhibitor), which is for the treatment of pulmonary arterial hypertension; GB004 (Hypoxia inducible factor-1a Stabilizer), which is for the treatment of inflammatory bowel disease; and GB1275 (CD11b Modulator), which is for the treatment of oncology indications.

Insmed is a biopharmaceutical company focused on improving the lives of patients with rare diseases. The company's proprietary Pulmovance? technology uses charge-neutral liposomes to deliver amikacin directly to the lungs where liposomal amikacin is taken up by the lung macrophages where the MAC infection resides. The company's product pipeline: INS1007, an oral, reversible inhibitor of dipeptidyl peptidase 1, an enzyme responsible for activating neutrophil serine proteases in neutrophils when they are formed in the bone marrow; INS1009, an investigational inhaled treprostinil prodrug formulation that has the potential to manage certain of the limitations of existing prostanoid therapies.

Intra-Cellular Therapies is a biopharmaceutical company focused on the discovery and clinical development of small molecule drugs that address medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system. The company's primary product candidate, Lumateperone is for the treatment of acute and residual schizophrenia, and for the treatment of bipolar disorder, including bipolar depression. The company's pipeline also includes preclinical programs that are focused on developing drugs for the treatment of schizophrenia, Parkinson's disease, Alzheimer's disease and other neuropsychiatric and neurodegenerative disorders.

Intuitive Surgical develops, manufactures, and markets the da Vinci? Surgical System and the Ion? endoluminal system. The systems consist of a surgeon console or consoles, a patient-side cart, a vision system, and proprietary instruments and accessories. The company's technology is designed to provide surgeons with a range of motion analogous to the motions of a human wrist, while filtering out the tremors inherent in a surgeon's hands. The company's primary platform for robotic-assisted surgery is its family of da Vinci Surgical Systems. The da Vinci Surgical System allows surgeons to operate while seated at an ergonomic console viewing a three-dimensional image of the surgical field.

Karuna is an innovative clinical-stage biopharmaceutical company focused on developing novel therapies to address disabling neuropsychiatric conditions characterized. The company's pipeline is built on the broad therapeutic potential of the company's lead product candidate, KarXT, an oral modulator of muscarinic receptors that are located both in the central nervous system, or CNS, and various peripheral tissues. KarXT is the company's proprietary product candidate that combines xanomeline, a novel muscarinic agonist, with trospium, an approved muscarinic antagonist, to preferentially stimulate muscarinic receptors in the CNS.

Krystal Biotech is a gene therapy company which is engaged in the developing and commercializing treatments for patients suffering from dermatological diseases. The company has developed a gene therapy platform, which it refers to as the Skin TARgeted Delivery platform, that consists of engineered, patented, viral vector based on herpes simplex virus 1, and skin-optimized gene transfer technology, to develop off-the-shelf treatments for dermatological diseases. The company's primary candidate, KB103, a gene therapy product, is in preclinical development to treat dystrophic epidermolysis bullosa, a rare and severe genetic disease.

LeMaitre Vascular is a provider of medical devices and human tissue cryopreservation services for the treatment of peripheral vascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons. The company's portfolio of peripheral vascular devices consists of brand name products that are used in arteries and veins outside of the heart and includes the LeMaitre valvulotome, the XenoSure biologic patch, the Pruitt F3 carotid shunt, VascuTape radiopaque tape, and Syntel embolectomy catheters. The company's principal product offerings are sold throughout the world, primarily in the United States, Europe and Asia/Pacific Rim.

Myriad Genetics is a precision medicine company acting as a trusted advisor to transform patient lives through molecular diagnostics. The company's molecular diagnostic tests include: myRisk? Hereditary Cancer for assessing the risks for hereditary cancers; BRACAnalysis? for assessing the risk of developing breast and ovarian cancer; riskScore? that improves the company's myRisk Hereditary Cancer test; GeneSight? to support psychotropic drug selection for depressed patients; Vectra?DA for assessing the disease activity of rheumatoid arthritis; and Prolaris? for assessing the aggressiveness of prostate cancer. The company also provides pharmaceutical and clinical services.

Nevro is a medical device company that has developed and commercialized the Senza? spinal cord stimulation, a neuromodulation platform for the treatment of chronic pain. The Senza system is approved to create electrical impulses from two Hz to 10,000 Hz, including the company's proprietary HF10 therapy, which allows for pain relief without paresthesia. Senza is consisted of leads, a trial stimulator, an implantable pulse generator (IPG), surgical tools, a clinician laptop programmer, a patient remote control and a mobile charger. These components enable physicians to implant the leads and the IPG, and patients to operate the system.

PAVmed is a medical device company engaged in developing a pipeline of medical technologies. The company's products pipeline include: CarpX?, which a minimally invasive device to treat carpal tunnel syndrome; EsoCheck? Technology, which is for detecting Barrett's Esophagus; PortIO?, which is an implantable intraosseous vascular access device; DisappEAR?, which are antimicrobial resorbable ear tubes; NextCath?, which is a self-anchoring short-term catheters; NextFlo?, which is an infusion systems with variable flow resistors; and Caldus?, which is a disposable tissue ablation devices, including for renal denervation, based on direct thermal ablation of the tissue using heated fluid.

PTC Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of clinically-differentiated medicines that provide benefits to patients with rare disorders. The company has the following products, Translarna? (ataluren) and Emflaza? (deflazacort), for the treatment of Duchenne muscular dystrophy, a rare, life threatening disorder. The company's gene therapy product candidates for rare monogenic diseases that affect the central nervous system (CNS) include PTC-AADC for the treatment of Aromatic L-Amino Acid Decarboxylase (AADC) deficiency, a rare CNS disorder arising from reductions in the enzyme AADC that results from mutations in the dopa decarboxylase gene.

REGENXBIO is a clinical-stage biotechnology company. The company's product candidates include: RGX-314, which is being developed as a gene therapy for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other additional chronic retinal conditions which cause total or partial vision loss for patients in the U.S., Europe and Japan; RGX-121, which is for the treatment of Mucopolysaccharidosis Type II; RGX-111, which is for the treatment of Mucopolysaccharidosis Type I; and RGX-181, which is for the treatment of late infantile neuronal ceroid lipofuscinosis type II disease; and RGX-501, which is for the treatment of homozygous familial hypercholesterolemia.

Sage Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing medicines to treat life-altering central nervous system disorders. The company's principal product candidate is ZULRESSO? (brexanolone) injection, a proprietary intravenous formulation of brexanolone for the treatment of postpartum depression (PPD). The company's other product candidate is SAGE-217, an oral compound that is being developed for PPD and major depressive disorder. The company also has a portfolio of other compounds that target GABAA receptors, which include SAGE-324 and SAGE-689. The company's second area of focus is the development of compounds that target the NMDA receptor, which include SAGE-718.

TTEC Holdings is a customer experience technology and services company. The company has four segments including Customer Strategy Services, which provides services in customer experience strategy and operations, insights, system and operational process optimization, and culture development; Customer Technology Services, which includes system design consulting, customer experience technology product, implementation and integration consulting services, and management of clients' cloud and on-premise solutions; Customer Growth Services, which provides technology-enabled sales and marketing solutions; and Customer Management Services, which includes customer experience delivery solutions.

Y-mAbs Therapeutics is a biopharmaceutical company focused on the development and commercialization of antibody-based therapeutic products for the treatment of cancer. The company has a range of product pipeline, including two pivotal-stage product candidates: naxitamab and omburtamab, which target tumors that express GD2 and B7-H3, respectively. The company is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma (NB), and radiolabeled omburtamab for the treatment of pediatric patients with central nervous system, leptomeningeal metastases, from NB.